Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine - Seite 2

As part of the agreement, Standard BioTools will support the development of Navignostics assays by collaborating on various aspects of protocols and instrument and software features. Additionally, both Navignostics and Standard BioTools plan to leverage their learnings to advance the science of IMC by co-publishing and presenting at scientific conferences in the coming year.

“In line with the Standard BioTools mission to accelerate breakthroughs in human health, our exciting partnership with Navignostics helps bring Imaging Mass Cytometry to the forefront of clinical research by generating the quality of data that can be translated into tangible results,” said Michael Egholm, President and CEO of Standard BioTools. “We are proud that the use of IMC and the advanced features of Hyperion XTi are core to their goal of developing methods and insights that will help cancer patients reach better outcomes, and we continue to enhance the system to further support their progress.”

Among key growth strategies for Standard BioTools is enabling new spatial biology applications in translational and clinical research by accelerating the development of turnkey panels, leading with new antibody targets through increased organic investment and partnership.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential benefits of research conducted using Standard BioTools products and technologies and the expected performance of such products and technologies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what is currently anticipated, including but not limited to risks relating to interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; potential product performance and quality issues; intellectual property risks; competition; uncertainties in contractual relationships; and reductions in research and development spending or changes in budget priorities by customers. Information on these and additional risks and uncertainties and other information affecting Standard BioTools business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2022, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law.